Quick Answer
CalciMedica, Inc. reported Net Income Loss of -$29.56 million for the year ending 2025.
- CalciMedica, Inc. showed a decrease of -115.8% in Net Income Loss from 2024 to 2025.
- This data is from CalciMedica, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$6.30 million | Q2 2019: -$10.26 million | Q3 2019: -$10.21 million | Q1 2020: -$7.79 million | Q2 2020: -$5.87 million | Q3 2020: -$4.72 million | Q1 2021: -$11.45 million | Q2 2021: -$7.71 million | Q3 2021: -$7.99 million | Q1 2022: -$3.63 million | Q2 2022: -$3.03 million | Q3 2022: -$2.58 million | Q1 2023: -$19.29 million | Q2 2023: -$6.30 million | Q3 2023: -$4.62 million | Q1 2024: $130.0 thousand | Q2 2024: -$3.95 million | Q3 2024: -$5.62 million | Q1 2025: -$5.04 million | Q2 2025: -$5.96 million | Q3 2025: -$7.80 million.
- Over the full 7 years of available data (2019 to 2025), CalciMedica, Inc.'s Net Income Loss has grown by 20.2%.
- Historical annual values: Fiscal year 2025: -$29.56 million | Fiscal year 2024: -$13.70 million | Fiscal year 2023: -$34.36 million | Fiscal year 2022: -$7.82 million | Fiscal year 2021: -$35.82 million | Fiscal year 2020: -$27.53 million | Fiscal year 2019: -$37.04 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: